Drug intelligence / Profile preview

hydrocortisone + urokinase

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

A combination therapy where hydrocortisone is used to manage anaphylactoid reactions that may occur during urokinase administration. Hydrocortisone is a glucocorticoid that reduces inflammation by binding to the glucocorticoid receptor, inhibiting inflammatory processes, and promoting anti-inflammatory genes. Urokinase is a thrombolytic agent used to dissolve blood clots in conditions such as pulmonary embolism and coronary artery thrombosis.

Targets

GR (Glucocorticoid receptor)PLAUR (Urokinase plasminogen activator receptor)PLG (Plasminogen)

Beyond the preview

Go deeper on hydrocortisone + urokinase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydrocortisone + urokinase.

Explore the full profile